Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ESMO 2016 /
Who should receive combination therapy for ER positive breast cancer?

7th - 11th Oct 2016

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 12.10.16
Views: 1554

Dr Michael Gnant - Medizinischen Universität Wien, Vienna, Austria

Dr Gnant speaks with ecancertv at ESMO 2016, reviewing the conference controversy session: Should combined endocrine therapy with targeted agents now be the standard of care for ER metastatic breast cancer?

Weighing cost and safety profile, Dr Gnant thinks further specificity in patient subtypes may streamline treatment selection.

He references the FALCON trial, which has demonstrated the superiority of fulvestrant over anastrazole, as illustrative of the problem in finding preferred combinations when one component may no longer be the best available.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation